Mei Ri Jing Ji Xin Wen·2025-10-29 23:13Group 1 - Huaxi Bio's subsidiary reached a settlement with Medytox, terminating arbitration and signing an agreement, which is expected to yield approximately 9.6 million HKD, positively impacting the consolidated financial statements [1] - The resolution of potential legal disputes and financial gains from the settlement are likely to enhance the company's valuation in the capital market, facilitating future financing and development [1] Group 2 - Peking University Pharmaceutical announced that its chairman and president, Xu Xiren, has been criminally detained, affecting the company's decision-making and operational stability [2] - The company has appointed Chen Yuezhong and Yu Mengchuan to temporarily assume the roles of chairman and president, respectively, but uncertainty remains regarding the new management's ability to stabilize operations and maintain performance [2] Group 3 - Fosun Pharma plans to spin off its vaccine business, Fosun Antigen, for a listing on the Hong Kong Stock Exchange, which is not expected to affect its control over the subsidiary [3] - The spin-off is anticipated to enhance Fosun Antigen's financing channels and market competitiveness, while also deepening Fosun Pharma's strategic positioning in the vaccine sector [3]